A Novel Radiopharmaceutical Conjugate That Can Be Labeled at Room Temperature for Specific Imaging of Infection Foci by Positron Emission Tomography (PET / CT): Ga-68 THP-Vancomycin

The novel radiopharmaceutical conjugate with a targeting agent and room-temperature chelator addresses the challenge of high false positives and structural degradation in Ga-68 labeling, enabling precise bacterial infection detection.

TR202607811A3Pending Publication Date: 2026-10-21EMİNE BUDAK
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TR202607811
Authority / Receiving Office
TR · TR
Patent Type
Applications
Current Assignee / Owner
Filing Date
2026-05-16
Publication Date
2026-10-21

AI Technical Summary

Technical Problem

Current nuclear medicine technologies face high false positive rates in distinguishing between sterile inflammation and true bacterial infections due to the use of F-18 FDG, and the high temperature labeling process for Ga-68 denatures thermolabile targeting agents like Vancomycin, compromising their biological activity.

Method used

A novel radiopharmaceutical conjugate comprising a targeting agent with high affinity for bacterial cell walls, a next-generation chelator that binds Ga-68 at room temperature, and a cold kit formulation for rapid preparation, allowing direct mixing with a Ga-68 generator eluate without heating, preserving the biological structure of Vancomycin.

Benefits of technology

Enables accurate detection of live Gram-positive bacterial cells, reducing false positives by maintaining Vancomycin's structure and activity, and providing a fast, practical solution for clinical use.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This invention encompasses a novel Ga-68 THP-Vancomycin radiopharmaceutical conjugate and its practical application method, developed for PET (Positron Emission Tomography) imaging for the differential diagnosis of sterile inflammation and active bacterial infection foci. Thanks to the THP chelator used in the invention, the labeling reaction with Ga-68 is carried out within minutes at room temperature (20°C - 30°C) and in a single vial ("Cold Kit" formulation) without the need for external heating. Thus, the biological activity of the vancomycin antibiotic, which is degraded at high temperatures, and its high specificity to the D-alanyl-D-alanine terminus in the cell wall of Gram-positive bacteria are preserved, resulting in a stable nuclear medicine imaging agent that prevents false positives from sterile inflammation.
Need to check novelty before this filing date? Find Prior Art

Description

Specific identification of infection foci using positron emission tomography (PET / CT). A Novel Radiopharmaceutical That Can Be Labeled at Room Temperature for Visualization Conjugate: Ga-68 THP-Vancomycin THE TECHNICAL FIELD TO WHICH THE INVENTION IS RELEVANT This invention has implications for the fields of nuclear medicine, radiopharmacy, and molecular imaging techniques. It is related to the invention, particularly regarding sterile inflammation and foci of active bacterial infection. a specific positron emission designed for use in differential diagnosis tomography (PET) agent and the method of rapid synthesis of this agent at room temperature It includes. PRINCIPLED STATE OF THE INVENTION (PRINCIPLED STATE OF THE ART) Commonly used in clinical nuclear medicine practice for visualizing infection foci. F-18 FDG is used. However, FDG is not all active ingredients that increase glucose metabolism. because it accumulates in leukocytes and inflammatory cells (post-operative processes, (Sterile implant reactions, autoimmune diseases, etc.) have a very high false positive rate. The level is high. This makes it difficult to distinguish between sterile inflammation and true bacterial infection. This makes it difficult to do. Alternatively, DOTA or NOTA chelating peptide conjugates were tested, which are Gallium- High temperatures of around 95°C are required to be labeled with the 68 (Ga-68) isotope. This high thermal energy makes it suitable for use as a targeting agent, such as Vancomycin. Tertiary / quadrilateral stages of sensitive glycopeptide antibiotics and thermolabile biomolecules It denatures their structures, eliminating biological activity and bacterial affinity. TECHNICAL PROBLEMS THAT THE INVENTION AIMS TO SOLVE The high false positive rates in current technology and with Ga-68 The high temperature (95°C) required during marking is thermolabile targeting. by causing structural degradation (denaturation) in biological agents (Vancomycin, etc.) Eliminating the activity are the fundamental technical problems that need to be solved. The invention also... In nuclear medicine clinics, a practical, fast, and externally heating-free solution It aims to solve the need for an implementation method. DESCRIPTION OF 35 INVENTIONS The invention is a three-part system designed to eliminate the technical problems mentioned above. a hybrid system and a formulation that facilitates the clinical use of this system It recommends: 1. Targeting Agent (Ligand): Located in the cell wall of Gram-positive bacteria. With high affinity and specificity to 40 D-alanyl-D-alanine terminal peptide residues. Vancomycin is an antibiotic with a glycopeptide structure that can bind to other substances. This agent, by binding directly to live bacterial cells, not to inflammation cells It provides differential diagnosis. 2. Next-Generation Chelator: Chelates Gallium-68 (Ga-68) radioisotope at room temperature. 45°C (20°C - 30°C) and physiological pH range, in a short time, with an external heating process. macrocyclic THP that can bind with high stability without requiring additional bonding tools. It is a (Tris(hydroxypyridinone)) chelator. 3. Cold Kit Formulation: Liquid for use in nuclear medicine clinics. or Ga-68 generator eluate contained in a single vial in lyophilized form. It can be mixed directly with 1 and be ready for injection within minutes. It is a practical formulation. TECHNICAL ADVANTAGES OF THE INVENTION  Preservation of Thermolabile Structure: Reaction chamber thanks to THP chelator Because this occurs at a certain temperature, the biological structure of the vancomycin molecule and The binding affinity with the bacteria is fully preserved.  Clinical Practicality ("Cold Kit" Advantage): No need for an external heating device. without being detected, by directly mixing with the generator eluate in a single vial. The product is ready for injection within minutes.  High Specificity (Accurate Diagnosis): Directly detects live Gram-positive bacterial cells. Because it targets the wall, it can cause sterile inflammation and implant reactions. This prevents false positives that may arise. 2

Claims

1. Detection of infection foci using nuclear medicine methods PET (Positron Emission) It is a radiopharmaceutical conjugate for imaging (CT scans), Its characteristic feature is that it is a glycopeptide antibiotic that targets the bacterial cell wall. Binding vancomycin with gallium-68 (Ga-68) radioisotope at room temperature THP (Tris(hydroxypyridinone)) is a macrocyclic chelator with the ability to It involves the chemical conjugation of molecules.

2. It is a radiopharmaceutical conjugate that conforms to Claim 1, and its characteristic feature is the presence of THP in its structure. via a chelator, with the Ga-68 radioisotope at room temperature (20°C - 30°C) and Gallium chelation without the need for an external heating process. It is the ability to accomplish it.

3. A radiopharmaceutical conjugate conforming to Claim 1, with the characteristic of being suitable for nuclear medicine. for use in clinics, in liquid or lyophilized form, in a single vial. contained and directly mixed with Ga-68 generator eluate in minutes in a "Cold Kit" formulation that can be made ready for injection It is the fact that.

4. The use of a radiopharmaceutical conjugate conforming to Claim 1 in the diagnosis of infection. Its use and characteristic feature is; sterile inflammatory foci and bacterial infection. To differentiate foci, D-type cells in the cell wall of Gram-positive bacteria were examined. It is the specific binding of alanyl-D-alanine to its terminus. 3